BioVaria Spin-off Awards go to Captain T Cell and Provirex

(PresseBox) ( Munich, Germany, )
On 22–23 May 2017, over 180 innovative minds gathered in Munich for the 10th BioVaria. Leading life scientists and their technology transfer partners presented the top projects originating from publicly funded research in Europe. Industry representatives and investors came from all over the world to learn about these inventions and evaluate opportunities for partnerships and collaboration. Their joint goal: transferring academic innovation into medically useful applications.

Altogether, 53 commercial opportunities from 50 European research institutes and universities were featured: innovative approaches in the fields of neurology, gene therapy, oncology, infections and metabolism.

To mark BioVaria’s 10th anniversary, the event was specially extended to two days, providing extra space not only for the birthday celebration, but also for an enlarged Spin-off Panel and keynotes on digital health.

This year’s interactive Panel featured 10 promising start-ups. A jury of seasoned life-science investors and executives selected Captain T Cell as the winner, based on its technology, business concept and performance during the panel. The start-up from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) develops an innovative approach to cancer immunotherapy. Their goal is to create a platform for the production of personalized, cancer-specific T cell receptors. With the help of these receptors, the body’s own T cells, so called ‘killer cells’, are able to find and specifically destroy cancer cells in the patient’s body. The BioVaria Jury Prize is worth EUR 1,000 plus one conference pass to the 17th Annual Biotech in Europe Forum for Global Partnering & Investment.

The BioVaria Audience Prize, another ticket to the Annual Biotech in Europe Forum, went to Provirex, a spin-off project from the Heinrich Pette Institute – Leibniz Institute for Experimental Virology (HPI). The team pioneers a ground-breaking approach to the therapy of HIV infection. Using a unique designer recombinase, the virus is specifically excised from the genome of infected cells without damaging the host cell. In contrast to existing treatment strategies, this would actually eliminate the virus, rather than merely keeping it in check. Both prizes were sponsored by Sachs Associates.

‘BioVaria is a great event because it brings all the right people together,’ says Dr Dirk Vocke, Associate Director, Innovation & Entrepreneurship, in the Healthcare business sector of Merck KGaA, Germany. ‘It was a pleasure for me to moderate this interactive Spin-off Panel, together with my colleague from Merck. We’ve seen some brilliant entrepreneurial approaches here, making it really difficult for the jury to reach a decision. Congratulations to the winning team!’ adds Dr Jeroen Bakker, Associate, Merck Ventures BV.

Further highlights were this year’s keynotes: Bart de Witte, Director Digital Health DACH at IBM, and Prof. Dr med. Dr phil. Torsten Haferlach, MLL Münchner Leukämielabor GmbH, shared valuable insights on their collaboration, highlighting the potential of cognitive computing for a new era of anti-cancer drug development and personalized care.

‘Digital health is a game-changing trend that opens new markets and offers a whole new world of collaboration opportunities across various industries, academic institutions and hospitals,’ says Dr Christian Stein, CEO of Ascenion. ‘This is an exciting prospect for BioVaria as it enters its second decade.’

The next BioVaria will take place on 24 April 2018 in Munich. Register at to receive news about the upcoming event.

Some of the technologies and spin-offs presented during BioVaria 2017 and a selection of photos will be available next week at

About BioVaria

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry.

Key features of BioVaria 2017:

Unique gathering of Europe's top scientists, technology transfer professionals, investors and industry representatives
Presentation of more than 50 licensable technologies and spin-offs originating from public research institutions and universities across Europe
Focus on patent-protected, commercially attractive opportunities covering therapeutics, diagnostics and research tools in the fields of cancer, infectious diseases, metabolism, autoimmune and neurodegenerative disorders, and in other disease areas
Interactive format combining 10-min oral presentations with a poster exhibition and plenty networking opportunities
Spin-off Panel presenting promising European life-science start-ups
Ample space to discuss scientific details face-to-face with the inventors
Jointly organized organized by Ascenion and a selected group of leading European technology transfer organizations
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an